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Rationale: R207910 (TMC207 or J) is a member of the diarylquino-
lines, a new family of antituberculous drugs with high bactericidal
activity when given daily in the murine model of tuberculosis.
R207910 exhibits a long half-life and thus is a good candidate for
once-weekly therapy of tuberculosis.
Objectives: To study the activity of once-weekly R207910 monother-
apy and combinations of R207910 with other antituberculous agents
(isoniazid, rifapentine, moxifloxacin, and pyrazinamide).
Methods: The established infection model of murine tuberculosis was
used. Colony counts were determined in the lungs.
MeasurementsandMainResults: Eight weeksofmonotherapy reduced
the bacillary load by 3 to 4 log10 for rifapentine and by 5 to 6 log10 for
R207910 (P , 0.05). The addition of rifapentine and isoniazid or
moxifloxacin did not improve the bactericidal activity of R207910
monotherapy. In contrast, the triple combination of R207910 plus
rifapentine plus pyrazinamide given once weekly for 2 months (i.e.,
a total of only eight administrations), was significantly (P , 0.05)
more active than R207910 monotherapy or other R207910 combi-
nations, and led to lung culture negativity in 9 of 10 mice, whereas all
lungs were culture positive in the groups treated with other drug
combinations. Moreover, R207910 plus rifapentine plus pyrazina-
mide given once weekly was more active than the current standard
regimen of rifampin plus isoniazid plus pyrazinamide given five
times per week.
Conclusions: The unprecedented activity of the triple combination of
R207910 plus rifapentine plus pyrazinamide suggests that it may be
feasible to develop a fully intermittent once-weekly regimen.
Keywords: tuberculosis; animal models; directly observed therapy;
R207910; diarylquinolines
Tuberculosis (TB) is the most important infectious disease
leading to mortality, after AIDS (1). Today, the treatment
recommended by the World Health Organization (WHO,
Geneva, Switzerland) combines four antituberculous drugs
(isoniazid, rifampin, pyrazinamide, and ethambutol) and must
be administered daily, largely in the initial 2 months, and at
least three times weekly during the continuation phase to
achieve a high cure rate (more than 95%). Because of the
complexity and length of this treatment, compliance is often
unsatisfactory. To improve compliance, WHO recommends
that treatment be ingested under the supervision of a health
care provider (the so-called directly observed therapy, or
DOT) (2). However, daily treatment is difficult to implement
in resource-poor countries where the majority of patients with
TB are located. Intermittent regimens, ideally given once
weekly, would simplify DOT. However, only a single antibi-
otic, rifapentine, has so far proven to be amendable for once-
weekly therapy of TB, and its use is restricted to the contin-
uation phase of treatment of HIV-negative patients who have
negative sputum smears at the end of the initial treatment
phase (3–5). A companion for rifapentine needs to have a long
plasma half-life to allow the development of a once-weekly
regimen. Moxifloxacin has proved to be active in the murine
tuberculosis model, when administered once weekly with
rifapentine and isoniazid, but was also shown to be less
sterilizing than standard daily treatment with rifampin plus
isoniazid plus pyrazinamide in the intravenously infected
mouse model (6). R207910 (TMC 207 or J) is a diarylquinoline
that inhibits both drug-sensitive and drug-resistant Mycobac-
terium tuberculosis in vitro through inhibition of the proton
pump ATP synthase. The minimal inhibitory concentration
(0.06 mg/ml againstM. tuberculosis) and the natural proportion
of resistant mutants in this species (1027 to 1028) are low (7).
When given once daily at 25 mg/kg for 2 months in murine
tuberculosis, R207910 is more bactericidal than other available
antituberculous drugs (8). R207910 exhibits a long half-life
(more than 2 d in the mouse), and its bactericidal effect is
maintained for 1 week in mice after a single dose of 100 mg/kg
(7). Thus, R207910 seems to be a good candidate to combine
with rifapentine for once-weekly therapy of tuberculosis. In
this study, we evaluated the bactericidal activity of R207910
alone and in combinations given once weekly in the murine
model of tuberculosis.
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Standard treatment of tuberculosis is long (6 mo) and
complicated (daily administration of antibiotics).
What This Study Adds to the Field
This study demonstrates that the diarylquinoline R207910
is active when administrated once weekly in the murine
model of tuberculosis. Drug combinations containing R207910
given once weekly are more active than the standard daily
regimen.
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METHODS
R207910 (J) was synthesized by Johnson & Johnson (Beerse, Belgium);
the other compounds were purchased from the following manufac-
turers: isoniazid from Laphal (Allauch, France); rifampin, rifapentine,
and pyrazinamide from Aventis (Antony, France); and moxifloxacin
from Bayer (Puteaux, France). The H37Rv strain of M. tuberculosis
was prepared as previously described (6). Mice were purchased from
the Janvier Breeding Center (Le Genest Saint-Isle, France). For each
of the three experiments, 4-week-old female Swiss mice were in-
travenously infected via the tail vein with 0.5 ml of M. tuberculosis
H37Rv suspension as follows: 310 mice infected with 5.2 3 106 colony-
forming units (CFU) (experiment 1), 110 mice infected with 1.5 3 106
CFU (experiment 2), and 120 mice infected with 6 3 106 CFU
(experiment 3). Two weeks postinfection, mice were randomly allo-
cated to treatment groups. In experiment 1, each treated group
contained 20 mice and the infected untreated control group contained
30 mice. The mice of the three treated control groups were treated with
either rifampin (10 mg/kg, 5 d/wk), isoniazid (25 mg/kg, 5 d/wk), or
rifapentine (10 mg/kg, 1 d/wk). The mice of the test groups were
treated with R207910 either (1) 5 days/week at 6.25, 12.5, or 25 mg/kg,
(2) twice weekly at 12.5, 25, or 50 mg/kg, (3) once weekly at 25, 50, or
100 mg/kg, or (4) once every 2 weeks at 50 or 100 mg/kg.
In experiment 2, each treated group contained 16 mice and the
infected untreated control group contained 30 mice. All test groups
were treated once weekly as follows: groups 2 and 3 were treated with
R207910 or rifapentine alone; group 4 was treated with the double
combination of R207910 and rifapentine; groups 5 and 6 were treated
with a triple combination of R207910 plus rifapentine plus isoniazid or
with R207910 plus rifapentine plus moxifloxacin.
In experiment 3, each treated group contained 10 mice and the
infected untreated control group contained 40 mice. Except for group
2, which was treated for 5 days/week with the WHO standard
treatment of rifampin plus isoniazid plus pyrazinamide, all treated
groups were treated once weekly as follows: groups 3, 4, and 5 were
treated with R207910, rifapentine, or moxifloxacin alone; group 6 was
treated with the double combination of R207910 plus rifapentine; and
groups 7, 8, and 9 were treated with the a triple drug combination of
R207910 plus rifapentine plus isoniazid, R207910 plus rifapentine plus
moxifloxacin, or R207910 plus rifapentine plus pyrazinamide.
Untreated control mice were killed the day after infection (Day
213) and at the start of treatment (Day 0). In experiment 1, 10 mice
were killed after 1 and 2 months of treatment in each treated group. In
experiment 2, eight mice were killed after 1 and 2 months of treatment
in each treated group. In experiment 3, all treated mice were killed
after 2 months of treatment. In each experiment, 10 mice were kept for
mortality assessment. The animal experiment guidelines of the Faculte´
de Me´decine Pitie´-Salpeˆtrie`re (Paris, France) were followed.
R207910 was prepared monthly in a hydroxypropyl-b-cyclodextrin
solution and kept at 48C. Other drug suspensions were prepared weekly
at the desired concentrations in distilled water containing 0.05% agar
and kept at 48C. All the drugs were given by gavage. In experiments 2
and 3, drugs were given at the following doses: R207910 125 mg/kg
weekly, rifampin 10 mg/kg daily, pyrazinamide 150 mg/kg daily or
300 mg/kg weekly, isoniazid 25 mg/kg daily or 75 mg/kg weekly, rifapentine
15 mg/kg weekly, moxifloxacin 400 mg/kg weekly in experiment 2 and
200 mg/kg weekly in experiment 3. Dosing of the drugs was selected to
provide areas under the concentration time curve (AUC) in mice that
were comparable with those achievable in humans at the usual dosing
(6, 7, 9). Moxifloxacin dosing was reduced from 400 to 200 mg/kg
between experiments 2 and 3 because new pharmacokinetic data
suggested that 200 mg/kg in mice is equipotent to the usual 400 mg/day
in human dosing (9).
The severity of infection and the effectiveness of treatments were
assessed on the basis of survival rate, spleen weight, gross lung lesions
(0, no lesions;1, fewer than 10 tubercles;11, more than 10 tubercles),
and the numbers of colony-forming units in the lungs. Enumeration of
colony-forming units and harvesting of lungs were done as previously
described (10). Colony unit counts were expressed as mean log10
(CFU) 6 standard deviation (SD). Mean colony-forming unit counts
were compared by Mann-Whitney test (using Minitab software; Mini-
tab, State College, PA). Differences were considered significant at the
95% level of confidence. Multiple comparisons were done in experi-
ments 2 and 3, and thus adjustment for multiple comparisons was made
by means of the Bonferroni correction. In experiment 2, in which there
were five test groups, P was adjusted to P 5 0.05/5 5 0.01. In
experiment 3, in which there were eight test groups, P was adjusted
to P 5 0.05/8 5 0.006. Proportions of positive mice after 2 months of
treatment were compared by chi-square test (Epi-Info; Centers for
Disease Control and Prevention, Atlanta, GA).
RESULTS
Experiment 1
Survival rate. All untreated control mice died between Day 26
and Day 42 due to the TB infection. All treatments prevented
mortality. Fifteen of 310 mice died because of gavage accidents
(4.8%): 1 in the isoniazid group, 1 in the R207910 (100 mg/kg 1/
7) group, 4 in the R207910 (25 mg/kg 1/7 group), 6 in the
R207910 (25 mg/kg 2/7) group, and 3 in the R207910 (25 mg/kg
5/7) group.
Spleen weights and gross lung lesions. At the start of treat-
ment (Day 0), all mice had more than 10 lung lesions and
splenomegaly (mean spleen weight, 637 6 170 mg). After
2 months, the majority of R207910-treated mice had none or
fewer than 10 lung lesions and the mean spleen weights for
treated groups were significantly lower than pretreatment
values (P , 0.05).
Colony-forming unit counts in lungs. The mean colony-
forming unit count in the lungs was 4.3 6 0.3 log10 the day
after infection and 6.0 6 0.3 log10 at the start of treatment
2 weeks later (Table 1). After 1 month of treatment, all mice
remained culture positive but the mean colony-forming unit
counts in all groups were significantly smaller than pretreatment
values (P , 0.05). The drop in colony-forming unit count was
the same for the same total weekly dose, irrespective of the
frequency of administration of R207910 (Figure 1). As an
example, the bactericidal activity was similar for 25 mg/kg 5/7,
TABLE 1. BACTERIAL COUNTS IN THE LUNGS OF MICE AFTER
1 AND 2 MONTHS OF TREATMENT WITH R207910 GIVEN
AT VARIOUS DOSES AND FREQUENCIES IN MURINE
TUBERCULOSIS: EXPERIMENT 1
Lung CFU (log10 6 SD)
Treatment Day 0* Month 1 Month 2
Infected, untreated 6.0 6 0.3
Treated control groups
H 25 mg/kg 5/7 4.0 6 0.4 3.5 6 0.7
R 10 mg/kg 5/7 4.1 6 0.5 2.9 6 1.3
P 10 mg/kg 1/7 4.4 6 0.2 2.8 6 1.1
R207910: 5 d weekly
J 25 mg/kg 5/7 2.4 6 0.5 0.4 6 0.6
J 12.5 mg/kg 5/7 3.2 6 0.4 2.2 6 1.2
J 6.25 mg/kg 5/7 4.3 6 0.5 3.2 6 0.7
R207910: Twice weekly
J 50 mg/kg 2/7 2.4 6 0.6 0.2 6 0.02
J 25 mg/kg 2/7 3.0 6 0.4 1.5 6 0.4
J 12.5 mg/kg 2/7 4.6 6 0.4 4.3 6 0.4
R207910: Once weekly
J 100 mg/kg 1/7 2.8 6 0.4 0.03 6 0.1
J 50 mg/kg 1/7 2.9 6 0.6 1.9 6 1.1
J 25 mg/kg 1/7 4.5 6 0.3 3.1 6 0.8
R207910: Once every 2 wk
J 100 mg/kg 1/14 3.7 6 0.3 2.1 6 0.7
J 50 mg/kg 1/14 4.8 6 0.4 4.3 6 0.6
Definition of abbreviations: H: isoniazid; J, R207910; P, rifapentine; R, rifampin.
Colony-forming unit counts are expressed as mean log10 (CFU) 6 standard
deviation (SD).
* Day 0 5 start of treatment.
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50 mg/kg 2/7, and 100 mg/kg 1/7 (total, 100 to 125 mg/kg/wk).
R207910 100 mg/kg once weekly was significantly more active
than rifampin 10 mg/kg given 5 days/week or rifapentine 10 mg/kg
given once weekly.
Experiment 2
Survival rate. All untreated control mice died between Day 15
and Day 33 after infection. All treatments prevented mortality.
One mouse out of 80 (1.25%) died because of a gavage accident
in group 4 on Day 30.
Spleen weights and gross lung lesions. At the start of treat-
ment (Day 0), all mice had more than 10 lung lesions and
splenomegaly (mean spleen weight, 643 6 79 mg). After
2 months, the majority of treated mice had none or fewer than
10 lung lesions and the mean spleen weights for treated groups
were significantly lower than pretreatment values (P , 0.05).
Colony-forming unit counts in lungs. The mean colony-form-
ing unit count in the lungs was 4.0 6 0.4 log10 the day after
infection and 6.1 6 0.6 log10 at the start of treatment 2 weeks
later. After 1 month of treatment, all mice remained culture
positive but the mean colony-forming unit counts in all groups
were significantly lower than pretreatment values (P , 0.01)
(Table 2). After 2 months of treatment, the colony-forming unit
count differed significantly between the R207910 monotherapy
group and the rifapentine monotherapy group: 0.4 6 0.7 log10
versus 2.3 6 1.3 log10, respectively. R207910 monotherapy
reduced the bacillary load by 5.7 log10 after 2 months, that is,
by an additional 1.9 log10 than rifapentine (P 5 0.007). After
1 month of treatment, the activity of R207910 was not signifi-
cantly enhanced by the addition of rifapentine or rifapentine plus
moxifloxacin. In contrast, the addition of rifapentine plus iso-
niazid enhanced the activity of R207910 by approximately 1 log10
(P 5 0.01). However, this difference was no longer significant
after 2 months of treatment, when R207910 monotherapy was as
active as R207910 plus rifapentine, R207910 plus rifapentine plus
moxifloxacin, and R207910 plus rifapentine plus isoniazid (P .
0.01). In addition, when comparing the proportion of mice with
positive organ culture after 2 months, the combinations did not
enhance the activity of R207910 monotherapy.
Experiment 3
Survival rate. All untreated control mice died between Day 5
and Day 35 after infection. Three mice of 10 treated with
moxifloxacin monotherapy died of tuberculosis on Day 8. Three
mice died of gavage accidents (3.8%): one mouse on Day 7 in
group 6 and 2 mice on Day 14, one in group 2, and one in group 3.
Spleen weight and gross lung lesions. At the start of treatment
(Day 0), all mice had more than 10 lung lesions and spleno-
megaly (mean spleen weight, 524 6 98 mg). After 2 months, the
majority of treated mice had none or fewer than 10 lung lesions
and the mean spleen weights for the treated groups were
significantly lower than pretreatment values (P , 0.05) except
in the moxifloxacin-treated group (more than 10 lung lesions
and no decrease in mean spleen weight).
Colony-forming unit counts in lungs. The mean colony-
forming unit count in the lungs was 6.1 6 0.6 the day after
intravenous inoculation, and 7.2 6 0.5 log10 at the start of
treatment 2 weeks later (Table 3). As observed in the first and
second experiments, R207910 monotherapy reduced the bacil-
lary load by 5 log10 after 2 months whereas rifapentine reduced
it by 4 log10 (P 5 0.005). Rifapentine plus moxifloxacin and
rifapentine plus isoniazid had little additive effect when com-
bined during 2 months with R207910, enhancing the drop in
colony-forming unit count by 0.1 and 0.5 log10, respectively
Figure 1. Bacterial counts (log10 colony-forming units) in lungs of
mice after 1 and 2 months of treatment with R207910 at 25 mg/kg for
5 days per week, 50 mg/kg twice weekly, or 100 mg/kg once weekly in
murine tuberculosis (experiment 1). CFU 5 colony-forming units.
TABLE 2. BACTERIAL COUNTS IN THE LUNGS OF MICE AND
PROPORTION OF MICE WITH NEGATIVE CULTURE AFTER 1
AND 2 MONTHS OF TREATMENT WITH R207910 CONTAINING
REGIMENS GIVEN ONCE WEEKLY IN MURINE TUBERCULOSIS:
EXPERIMENT 2
Treatment
Group
Log10 CFU Proportion of
Negative Mice
at 2 moDay 0* Month 1 Month 2
1: Untreated 6.1 6 0.6
2: J 3.2 6 0.5 0.4 6 0.7 2/8
3: P 4.7 6 0.3 2.3 6 1.3 1/8
4: JP 2.9 6 0.3 0.4 6 0.4 1/7
5: JPH 2.1 6 0.7 0.9 6 0.8 1/8
6: JPM 2.8 6 1.4 0.2 6 0.5 2/8
Definition of abbreviations: H 5 isoniazid, 75 mg/kg; J 5 R207910, 125 mg/kg;
M 5 moxifloxacin, 400 mg/kg; P 5 rifapentine, 15 mg/kg.
Colony-forming unit counts are expressed as mean log10 (CFU) 6 standard
deviation (SD).
* Day 0 5 start of treatment.
TABLE 3. BACTERIAL COUNT IN THE LUNGS OF MICE, AND
PROPORTION OF MICE WITH NEGATIVE CULTURE, AFTER
2 MONTHS OF TREATMENT GIVEN ONCE WEEKLY IN MURINE
TUBERCULOSIS: EXPERIMENT 3
Treatment Group Log10 CFU Proportion of Negative Mice
1: Untreated D0 7.2 6 0.5 0/20
2: RHZ* 2.2 6 0.6 0/9
3: J 2.0 6 0.8 0/9
4: P 3.3 6 0.6 0/10
5: M 6.4 6 0.5 0/7
6: JP 1.6 6 0.9 1/9
7: JPH 1.5 6 0.8 0/10
8: JPM 1.9 6 0.7 0/10
9: JPZ 0.2 6 0.7 9/10
Definition of abbreviations: D0 5 Day 0 (start of treatment); H 5 isoniazid, 25
mg/kg 5 days/week or 75 mg/kg once weekly; J 5 R207910, 125 mg/kg; M 5
moxifloxacin, 200 mg/kg; P 5 rifapentine, 15 mg/kg; R 5 rifampin, 10 mg/kg;
Z 5 pyrazinamide, 150 mg/kg 5 days/week or 300 mg/kg once weekly.
Colony-forming unit counts are expressed as mean log10 (CFU) 6 standard
deviation (SD).
* Given five times weekly.
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(P . 0.05). In contrast, the mean colony-forming unit count in
the lungs of mice receiving R207910 plus rifapentine plus
pyrazinamide (0.2 6 0.7) was significantly smaller than the
mean colony-forming unit count in the lungs of mice receiving
R207910 alone (P 5 0.0006), R207910 plus rifapentine (P 5
0.0027), R207910 plus rifapentine plus moxifloxacin (P5 0.0008),
or R207910 plus rifapentine plus isoniazid (P 5 0.001). More-
over, the mean colony-forming unit count in mice treated once
weekly with the triple combination of R207910 plus rifapentine
plus pyrazinamide was 2 log10 lower than that in mice treated
daily with the standard regimen of rifampin plus isoniazid plus
pyrazinamide (P 5 0.0009). When comparing the proportion of
mice with negative organ culture, the triple combination of
R207910 plus rifapentine plus pyrazinamide was also the only
group significantly different from the others. Indeed, 9 of 10
mice were culture negative with this combination whereas in the
other groups all mice were culture positive, except a single mouse
in the R207910 plus rifapentine group.
DISCUSSION
Although the strong antituberculous activity and long half-life
of rifapentine were established years ago, its use in clinical
practice is limited by the lack of a companion drug with a long
plasma half-life. Once-weekly rifapentine and isoniazid in the
continuation phase was found less effective than comparator
regimens based on rifampin and isoniazid (11, 12). Indeed,
because combination therapy is necessary to prevent the emer-
gence of resistance, treatment of tuberculosis must always include
at least two active drugs. When rifapentine is combined with
isoniazid in once-weekly regimens, rifapentine remains the only
active drug after the clearance of isoniazid, because of the short
half-life of the latter (1 to 3 h). This exposes patients to the risk
of treatment failure due to the selection of rifamycin-resistant
mutants, as was demonstrated in a controlled trial (5, 13). There
has been renewed interest in rifapentine since the discovery of
moxifloxacin, a fluoroquinolone with high activity against
M. tuberculosis and exhibiting a plasma half-life of 9 hours in
humans. In the murine model of tuberculosis, some rifapentine-
and moxifloxacin-containing drug combinations given once
weekly are as active as the standard daily regimen rifampin
plus isoniazid plus pyrazinamide. Such rifapentine-containing
regimens are even more active when given twice weekly (6, 14).
R207910 has two important characteristics favoring its use
for intermittent therapy of tuberculosis (1): a long half-life (173 h
in man, 2 d in mouse) and (2) a low proportion of resistant
mutants (1027 to 1028) (7). In a pilot study we evaluated the
activity of the daily administration of R207910 in the murine
model of tuberculosis (7). At the dose of 25 mg/kg, R207910
reduced the bacillary load by approximately 2.5 to 3.0 log10
CFU per month and was as active as the standard daily regimen
of rifampin plus isoniazid plus pyrazinamide. In the present
study the bactericidal activity of R207910 was shown to be
equivalent when administered (1) once weekly at 100 mg/kg, (2)
twice weekly at 50 mg/kg and (3) 5 days/week at 25 mg/kg (2.5
to 3.0 log10 reduction of the bacillary load per month). Thus the
bactericidal activity of R207910 correlates with the total weekly
dose, irrespective of the frequency of administration. In the
current study, a weekly dose of R207910 at 100 to 125 mg/kg
exceeded the activity of a once-weekly dose of rifapentine at
15 mg/kg. Moreover, once-weekly monotherapy with R207910
was as active as the standard daily triple-drug regimen of rifampin
plus isoniazid plus pyrazinamide.
The addition of isoniazid and rifapentine increased the
bactericidal activity of R207910 monotherapy after 1 month of
treatment. The speed of bacillary killing is important in the
treatment of patients with tuberculosis as it reduces their
contagiousness and contributes to the prevention of selection
of resistance. However, the most impressive result obtained in
this study is the activity of R207910 combined with rifapentine
and pyrazinamide. Indeed, this triple-drug combination given
once weekly decreased the bacillary load by 7 log10, and
resulted in negative lung cultures in 9 of 10 mice after only
2 months of therapy, that is, after only 8 weekly doses. This
weekly triple-drug combination was even more active (P 5
0.0009) than the standard treatment rifampin plus isoniazid plus
pyrazinamide given 5 days/week, an activity that is unprece-
dented for any weekly regimen (10, 15, 16). Indeed, the triple
combination of rifapentine plus moxifloxacin plus pyrazinamide
must be administered twice weekly and must be preceded by an
intensive phase during which the treatment is given daily to
obtain the same decrease in bacillary load (14). Interestingly,
the triple combination of R207910 plus rifapentine plus pyr-
azinamide given once weekly displayed a 2-month bactericidal
activity equivalent to that of R207910 plus rifampin plus
pyrazinamide given 5 days/week obtained in one study (8).
Although the present work was not designed to investigate
synergism between the antituberculous agents used, the impres-
sive activity of the triple combination of R207910 plus rifapen-
tine plus pyrazinamide that led to a decrease in bacillary load
significantly higher than that obtained with the double combi-
nation R207910 plus rifapentine, strongly suggests that R207910
and pyrazinamide act synergistically even when given once
weekly. A synergistic interaction between pyrazinamide and
R207910 was revealed in earlier studies in which both drugs
were administered 5 days/week (8). The activity in once-weekly
regimens suggests that the rather short half-life of pyrazinamide
in mice does not hamper a synergistic interaction. It would be
interesting to determine the lowest active dose of pyrazinamide
needed in combination studies with the diarylquinoline, as
pyrazinamide is rather toxic at the current human dose (17).
It should be determined which once-weekly R207910-con-
taining drug combinations result in acceptable relapse rates in
the murine model. Although rifapentine associated with moxi-
floxacin or isoniazid did not substantially enhance the bacteri-
cidal activity of R207910 after 2 months, it is possible that these
drugs increase the sterilizing activity and consequently reduce
the total duration of therapy. It is indeed established that
moxifloxacin increases the sterilizing activity of once-weekly
regimens despite having little bactericidal activity when given
alone (10, 18). Moreover, isoniazid and moxifloxacin may also
be necessary for early bactericidal activity. The pharmacoki-
netic properties of R207910 and the impressive bactericidal
activity of the triple combination of R207910 plus rifapentine
plus pyrazinamide suggest the possibility of developing a fully
intermittent regimen against drug-sensitive tuberculosis. Such
a regimen would significantly increase compliance and facilitate
DOT. Relapse experiments should focus on the possible emer-
gence of resistant mutants as this has been the main problem
associated with the development of a once-weekly antitubercu-
lous regimen in humans.
R207910 could also be tested as a backbone of intermittent
treatment against latent tuberculosis. A clinical trial has dem-
onstrated that a 3-month once-weekly regimen containing iso-
niazid plus rifapentine is as effective, and less toxic, than a
2-month daily rifampin plus pyrazinamide regimen (19). In view
of the superiority of R207910 over rifapentine in the mouse
model, a shorter regimen could be tested.
There are some limitations to the extrapolation of the
present results to the human situation. First, because tubercu-
losis develops much faster in mice (mice die in less than 2 mo),
the mouse model may underestimate efficacy in humans.
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Moreover, mice do not develop lung cavities and the spread of
the bacilli is hematogenous rather than bronchogenous. For
these reasons, we included the standard WHO treatment con-
sisting of rifampin, isoniazid, and pyrazinamide as a control
group. Because the activity of this regimen is well established in
humans as well as in the murine model, it facilitates interpre-
tation of the results.
A second limitation of our studies is the dose of R207910
that was used. To be predictive of what will happen in humans,
the doses used in the mouse model should generate pharmaco-
kinetic parameters similar to those observed in humans. In
human volunteers, 400 mg of R207910 given orally was well
tolerated and led to a Cmax of about 5 mg/L and an AUC of
52 mghour/L. In mice, oral gavage with R207910 at 25 mg/kg
leads to a Cmax of 1.2 mg/L and an AUC of 19 mghour/L.
Assuming dose linearity, the expected Cmax and AUC after a dose
of 125 mg/kg should be approximately 6 mg/L and 100 mghour/L,
respectively (7). Thus the Cmax obtained in mice treated with
125 mg/kg is comparable to that obtained in humans with 400 mg,
and the AUC is comparable to that obtained in humans with
800 mg. Further pharmacokinetic studies in mice and in humans
are warranted to precisely delineate the equipotency of once-
weekly doses of R207910 in mice and humans.
A third limitation is that rifapentine may induce the metab-
olism of R207910 in humans and lower its plasma concentra-
tions, similar to what has been observed with rifampin. We do
not know whether such drug–drug interaction exists in the
murine model.
In conclusion, R207910 displays a similar high bactericidal
activity against Mycobacterium tuberculosis in mice whether
given weekly or daily, provided that the total weekly dose of
drug is the same. The triple-drug combination of R207910 plus
rifapentine plus pyrazinamide displays unprecedented bacteri-
cidal activity in mice, and raises the possibility of developing
a new, fully intermittent short-course regimen for the therapy of
tuberculosis.
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